NET ASSET VALUE – 31 October 2025
On the 31 October 2025 Flerie AB's Net Asset Value (NAV) was SEK 3,654 million and NAV per share was SEK 47.18.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 435 | 5.62 | 11.9% |
| Empros Pharma | 79% | 204 | 2.64 | 5.6% |
| Atrogi | 44% | 197 | 2.54 | 5.4% |
| Xspray Pharma | 18% | 189 | 2.44 | 5.2% |
| KAHR Medical | 35% | 172 | 2.22 | 4.7% |
| Xintela | 59% | 171 | 2.21 | 4.7% |
| Bonsai Biotherapeutics | 100% | 131 | 1.69 | 3.6% |
| Microbiotica | 10% | 124 | 1.60 | 3.4% |
| Lipum | 57% | 118 | 1.52 | 3.2% |
| Geneos Therapeutics | 12% | 91 | 1.17 | 2.5% |
| Mendus | 23% | 86 | 1.11 | 2.3% |
| AnaCardio | 13% | 79 | 1.02 | 2.2% |
| EpiEndo Pharmaceuticals | 9% | 54 | 0.70 | 1.5% |
| Vitara Biomedical | 11% | 47 | 0.61 | 1.3% |
| Egetis Therapeutics | 1% | 32 | 0.41 | 0.9% |
| Buzzard Pharmaceuticals | 14% | 32 | 0.41 | 0.9% |
| Amarna Therapeutics | 58% | 11 | 0.14 | 0.3% |
| Strike Pharma | 18% | 11 | 0.14 | 0.3% |
| Alder Therapeutics | 30% | 8 | 0.10 | 0.2% |
| Total | 2,191 | 28.29 | 60.0% | |
| Commercial Growth | ||||
| NorthX Biologics | 61% | 202 | 2.61 | 5.5% |
| Symcel | 30% | 192 | 2.48 | 5.3% |
| Chromafora | 30% | 73 | 0.94 | 2.0% |
| Nanologica | 44% | 48 | 0.62 | 1.3% |
| Frontier Biosolutions | 2% | 26 | 0.34 | 0.7% |
| Bohus Biotech | 45% | 0 | 0.00 | 0.0% |
| Total | 541 | 6.98 | 14.8% | |
| Limited Partnerships, total | 105 | 1.36 | 2.9% | |
| Assets related to Portfolio companies | 335 | 4.32 | 9.2% | |
| Other assets and liabilities | 483 | 6.23 | 13.2% | |
| Net Asset Value | 3,654 | 47.18 | 100.0% | |